PD-1 blockade with cemiplimab in advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1)
Cemiplimab shrank tumours in about half of patients with metastatic or locally advanced cutaneous squamous cell carcinoma, a highly mutated skin cancer with almost no previous treatment options, leading to the first approval for the disease.
Overview
Phase 1 expansion cohort (26 patients) and phase 2 study (59 patients) of cemiplimab in patients with metastatic or locally advanced cutaneous squamous cell carcinoma not amenable to curative surgery or radiotherapy.
Objective response was 50 percent in the phase 1 cohort and 47 percent in the phase 2 metastatic cohort, with most responses durable beyond six months and typical immune-related toxicity.
- Objective response 50 percent (phase 1) and 47 percent (phase 2 metastatic cohort).
- Durable responses exceeding six months in the majority of responders.
PD-1 blockade is the first-line systemic treatment for advanced cutaneous squamous cell carcinoma, including on the lip, and cemiplimab has since moved into neoadjuvant and adjuvant use.
- Single-arm; transplant recipients and immunosuppressed patients were excluded.
Similar pages
not linked directly; found by shared links- Key paperC-POST: adjuvant cemiplimab versus placebo in high-risk cutaneous squamous cell carcinoma
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab, New England Journal of Medicine.
- Key paperNeoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab, New England Journal of Medicine.
- TrialStudy of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab.
- TrialStudy Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab.
- Key paperRadiotherapy plus cetuximab for locoregionally advanced squamous cell carcinoma of the head and neck
- TrialAn Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab.
- Key paperEMPOWER-Cervical 1: cemiplimab versus chemotherapy in recurrent cervical cancer after platinum
- Key paperEORTC 22931: postoperative irradiation with or without concomitant cisplatin for locally advanced head and neck cancer